Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A cost- energy-efficient treatment technology to remove pharmaceutical pollutants from water (PFS)

Framework: Horizon 2020 — Societal Challenges
Programme: Climate action, environment,  resource efficiency and raw materials
Action type: SME instrument
Countries involved: Sweden
Call: Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials (H2020-SMEINST-2-2016-2017, 2017)
Start date: 2018-03-01
End date: 2020-06-30
Duration (months): 28.0
Total project cost (EUR): 2962500.0
EU funding (EUR): 2073750.0
Participants: 1
Project status: CLOSED

Widely used pharmaceuticals (synthetic or natural chemicals found in prescription medicines, over-the-counter therapeutic drugs & veterinary drugs) are finding their way into the drinking water supply via wastewater treatment facilities, posing serious threats to public health globally. The problem is that modern wastewater treatment facilities are not designed for effective removal of pharmaceuticals or similar organic compounds. Upcoming EU legislation will make such removal mandatory. Pharem Biotech brings to market PFS—the first patented enzyme-carrying filtration system capable of removing a large range of organic pollutants (pharmaceuticals and other biological active compounds such as bisphenol A, antibiotics, hormone disruptors, etc.). PFS is a filtration solution that can be easily installed at most of wastewater treatment facilities. Its compact size makes it particularly useful for urban wastewater treatment plants. PFS is based on modified enzymes which are 200 times more effective than native enzymes, resistant to low temperature, resistant to low pH and with high levels of stability and activity. Compared to alternative purification methods, PFS is very cost-efficient, and requires no energy to run. As the total EU yearly investments in its wastewater treatment facilities and related infrastructure are expected to reach €25bn per year in 2015-2020, Pharem Biotech is addressing the market of 70,000 facilities in EU processing 100bn litres of water per day in total. During a successful Phase 1 project, Pharem Biotech validated the market and commercial feasibility of PFS, and selected the trial cases to validate the technology as well as key target markets to approach. In this Phase 2 project Pharem Biotech will industrialize PFS, validate it in trial cases and prepare for commercial roll out with the objective is to deploy 50 PFS systems before 2020 and reach revenue of €34m. The requested EC contribution is €2.07m.

Keywords: wastewater,water treatment,wwtp,pharmaceuticals
Effects of stakeholder consultations on inputs, processes and outcomes of executive policymaking (CONSULTATIONEFFECTS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Norway
Call: ERC Starting Grant (ERC-2018-STG, 2018)
Start date: 2019-04-01
End date: 2025-06-30
Duration (months): 75.0
Total project cost (EUR): 1424856.0
EU funding (EUR): 1424856.0
Participants: 1
Project status: SIGNED

Consultations with stakeholders (citizens and interest organizations) are frequently used by executive bureaucracies to design policies and formulate legislation. National ministries, regulatory agencies and the European Commission employ a variety of consultation designs that combine different practices - public consultations, public hearings, workshops, expert groups, advisory committees. Consultations are key to European economic growth strategies such as the Lisbon Agenda and Europe 2020. Despite their near ubiquitous use and legitimising rhetoric, there is currently no systematic analysis assessing empirically the assumption that stakeholders’ participation in policymaking via consultations improves policymaking and results in better outcomes and more legitimate governance. This project aims to address this gap and to systematically investigate and explain the effects of stakeholder consultation designs on policy inputs, processes and outcomes of executive policymaking in 29 political systems: all 28 EU Member States and the EU polity. The project pioneers a path-breaking conceptualisation of consultation designs as representative institutions similar to electoral systems. They play a key instrumental role in the institutional balance of power and constitute a new source of bureaucratic reputation, autonomy and power. The project elaborates an original theory explaining consultation effects on policymaking that accounts for the intrinsic challenges of democratising twenty-first century bureaucracies, and the inherent trade-offs of democratic and technocratic policymaking. Empirically, the project breaks new ground by designing an ambitious data collection strategy aimed to construct an unprecedented, cross-national, comparative dataset on stakeholder consultation designs and characteristics of inputs, processes, outputs and outcomes observed at policy proposal level, across policy areas and political systems.
Creating links to speed-up innovation in the bio economy (BioLinX)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: Coordination and support actions
Countries involved: Germany,Germany,Italy,Italy,Sweden,Sweden,Belgium,Belgium,Bulgaria,Netherlands,Netherlands
Call: Bridging research and innovation efforts for a sustainable bioeconomy (H2020-ISIB-2014-1, 2014)
Start date: 2015-07-01
End date: 2018-06-30
Duration (months): 36.0
Total project cost (EUR): 2000096.26
EU funding (EUR): 1997434.26
Participants: 12
Project status: CLOSED

BioLinX will bridge research and innovation efforts in the bioeconomy by building three large clusters in Europe and initiating within them a range of powerful linking and innovation acceleration processes. The BioLinX partners have leading roles in the bioeconomies of South West Netherlands and Flanders, the Nordic Countries and Northern Italy and in the lignocellulose, agro- and agro-waste feedstock sectors. The partners are all pioneers of systematic innovation management and cluster acceleration practices and between them have leading roles in over 45 current or recent collaborative bioeconomy projects. From this strong starting point they will select sixty or more FP7 and Horizon 2020 biobased projects from all stages of the value chain, form the BioLinX clusters and develop among them brokerage, collaborative innovation and business acceleration dynamics. Specific objectives are: 1. Selecting and scouting more than 60 high potential bio-economy projects, 2. Developing a network of key regional bioeconomy clusters (i.e. RIS3 regions or equivalent) covering 3 geographical regions (north, central, south) 3. Analysing, clustering and focusing selected FP7 and H2020 projects as well as the network of RIS3 bio-economy regions, 4. Implementing the Innovation Linking & Support Programme consisting of activities focusing on Brokerage and Innovation incubation, Business development, finance and funding, Identifying and sharing good practices and Advocacy, communication and dissemination.

Keywords: smart specialisation regions,collaborative innovation,business acceleration dynamics,brokerage and linking,finance and funding,sharing of good practises,biobased economy,pace of innovation
Brownian geometry: at the interface between probability theory, combinatorics and mathematical physics. (GeoBrown)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Mathematics
Panel description: All areas of mathematics, pure and applied, plus mathematical foundations of computer science, mathematical physics and statistics
Countries involved: France
Call: ERC Advanced Grant (ERC-2016-ADG, 2016)
Start date: 2017-05-01
End date: 2023-04-30
Duration (months): 72.0
Total project cost (EUR): 1263607.0
EU funding (EUR): 1263607.0
Participants: 2
Project status: SIGNED

The main purpose of this proposal is to explore the canonical models of planar random geometry that have been introduced in the recent years. We call this theory Brownian geometry because one of the central objects, the Brownian map, arises as the universal scaling limit of many discrete models of large random graphs embedded in the plane, in a way very similar to Brownian motion, which is the continuous limit of many different classes of random paths. The preceding scaling limit holds for the Gromov-Hausdorff distance on compact metric spaces. Furthermore, recent developments show that, in addition to its metric structure, the Brownian map can be equipped with a conformal structure. Our objectives will be to combine the different approaches to develop a systematic study of the Brownian map and its variants called the Brownian disk and the Brownian plane, as well as of the associated discrete models, which are finite graphs embedded in the plane or infinite random lattices such as the uniform infinite planar triangulation. We will also study random phenomena in random geometry, starting with random walks on infinite random lattices, with the ultimate goal of constructing Brownian motion on our continuous models. A question of importance in mathematical physics is to understand the behavior of statistical physics models in random geometry. Another fundamental question is to connect the conformal structure of the Brownian map with the conformal embeddings that are known to exist for discrete planar maps. The field of random geometry gives rise to exceptionally fruitful interactions between specialists of probability theory, theoretical physicists and mathematicians coming from other areas, in particular from combinatorics. To ensure the best chances of success for the proposed research, we will rely on the expertise of several members of the Laboratoire de Mathématiques d'Orsay, and on the unique environment of Université Paris-Sud and neighboring institutions.

Keywords: random geometry,random planar map,triangulation,brownian map,conformal structure,scaling limit,random walk,statistical physics model
Centre of Excellence for Autonomous and Cooperative Robotic Systems (ACROSS)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Sweden,Croatia
Call: Teaming Phase 1 (H2020-WIDESPREAD-04-2017-TeamingPhase1, 2017)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 399937.5
EU funding (EUR): 399937.5
Participants: 3
Project status: CLOSED

The overall objective of the project is to create a Centre of Excellence for Autonomous and Cooperative Robotic Systems in Croatia (ACROSS CoE), which will be at the forefront of research and innovation of novel methodologies and advanced engineering approaches in the targeted domains. ACROSS CoE will be created and run as a long-term joint venture between the UNIZG-FER ̵ University of Zagreb Faculty of Electrical Engineering and Computing, the KTH ̵ Royal Institute of Technology, and the ICENT ̵ Innovation Centre Nikola Tesla. To achieve the overall objective, the proposal focuses on long-term objectives for Teaming Phase 2 and on one-year objective for Teaming Phase 1. Long-term objectives of the Phase 2 and beyond are: (i) Reinforcing scientific capacity and innovation performances in autonomous and cooperative robotic systems, (ii) Increasing scientific visibility and reputation at international level, and (iii) Improving responses to socioeconomic needs of Croatia. ACROSS CoE will achieve these objectives by striving for high quality research, in line with international standards of excellence, and by directing its research towards areas serving the technological needs identified by the Croatian Smart Specialisation Strategy. The ultimate objective of the Phase 1 is to produce an extensive, detailed, and robust Business Plan for ACROSS CoE; and to achieve this, the plan will be built upon (i) Assessment of the existing ACROSS ecosystem and (ii) Development of roadmaps for achieving ACROSS CoE excellence. The ACROSS project is relevant to the work programme since the main goal is to create a new Centre of Excellence in Croatia, a low R&I performing country, by building upon partnership with KTH, a world leading scientific and innovation institution. Creation of the ACROSS CoE will help Croatia in attaining a competitive position in the global value chains, thus also contributing to Europe’s competitiveness and its ability to address future societal challenges.

Keywords: robotics,autonomous systems,cooperative robotic systems
Systemic approach to Reduce Energy demand and CO2 emissions of processes that transform agroforestry waste into High Added value Products. (REHAP)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Sustainable, resource-efficient and low-carbon technologies in energy-intensive process industries
Action type: Innovation actions
Countries involved: Germany,Germany,Spain,Spain,Spain,Spain,Italy,Italy,Italy,Spain,Italy,Spain,Finland,Belgium,France,United Kingdom,United Kingdom
Call: Industrial technologies for the valorisation of European bio-resources into high added value process streams (H2020-SPIRE-2016, 2016)
Start date: 2016-10-01
End date: 2021-03-31
Duration (months): 54.0
Total project cost (EUR): 8157789.3
EU funding (EUR): 6743545.0
Participants: 20
Project status: CLOSED

Europe's position in the production of biochemicals from biomass and by-products is limited to a few compounds, while their demand is among the largest in the world. However, Europe has a lot of world leader chemical companies. On the other hand, lignocellulosic waste constitutes one of the most abundant resources without competing with food chain. REHAP’s 16 partners aim at revalorizing agricultural (wheat straw) and forestry (bark) waste through its recovery, and primary (sugars, lignin, tannins) and secondary (sugar acids, carboxylic acids, aromatics and resins) processing to turn them into novel materials, and considering Green Building as business case. The project will provide reductions in utilization of fossil resources of 80-100%, and energy utilization and CO2 emissions above 30%. Specifically, building blocks (1,4 and 2,3-Butanediol, estherpolyols), materials (PUs, phenolic resins, modified hydrolysis lignin) and products (wooden boards, insulation foams, cement, adhesive) will be obtained: • Isolation of tannins and carbohydrates from forestry waste to turn them into bio-phenolic resins for wooden panels and isocyanate-free polyurethanes (PU) for insulating foams, respectively. • Isolation of lignin and carbohydrates from agricultural waste to turn them into bio-phenolic resins for wooden panels and biosuperplasticizers for cement, and estherpolyol PU for adhesives, respectively. • Fire retardant lignin and sugar-based additives will be also developed. Developed processing technologies (chemo/thermo/enzymatic and fermentation) will be optimized at pilot scale (TRL6-7) for further exploitation and replication of results. All products will be integrated in a prototype to demonstrate industrial applicability into the Green Construction sector. Throughout the project, Life Cycle and Cost Assessment, market analysis, business plan, waste management strategy and measures for future standardization will be implemented using a systemic perspective approach.

Keywords: lignocellulose waste,lignin,tannins,sugars,building blocks,up scaling,process engineering,construction sector,bioresins,bioadhesives,bio insulation foam,biosuperplastificant,revalorization
Bombs, Banks and Sanctions: A Sociology of the Transnational Legal Field of Nuclear Nonproliferation (PROSANCT)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Institutions, Governance and Legal Systems
Panel description: Political science, international relations, law
Countries involved: Switzerland
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-03-01
End date: 2022-08-31
Duration (months): 66.0
Total project cost (EUR): 1499788.0
EU funding (EUR): 1499788.0
Participants: 1
Project status: CLOSED

As the critical sanctions against Iran’s nuclear program demonstrate, the implementation of sanctions (SANCT) against nuclear proliferators (PRO) has lead to the creation of a global system of surveillance of the financial dealings of all states, banks and individuals, fostered by the United Nations Security Council (UNSC) resolutions. This is a new and unprecedented development in transnational governance. This research will apply a sociological perspective to the study of this new “transnational legal order” by analyzing how new actors, institutions and legal technologies shape the processes of norm-creation and rules-implementation in the field of nuclear nonproliferation. PROSANCT asks: How have the social characteristics of the actors in charge of designing and implementing sanctions influenced the creation of new norms in the field of nonproliferation? Which legal technologies and which discursive practices have these new actors developed to impose their authority and their legitimacy on the regulation of global financial transactions? Answering these questions will generate a better understanding of key processes in global governance: 1) the increasing role of the UNSC as a global legislator through top-down processes of norms diffusion; 2) the “financialization” of global regulation, with the increasing role played by international financial institutions, which were historically foreign to the field of nuclear nonproliferation; and 3) the “judicialization” of the enforcement of sanctions, and the associated reconfiguration of relations between executive and judicial authorities in charge of punishing nuclear proliferators and sanctions-evaders at the domestic level. To study these legal processes in various contexts (the United States and Europe), PROSANCT applies a multi-methods approach that combines interview-based methods with politicians, high-level bureaucrats and diplomats, and experts, and archival research.

Keywords: transnational legal fields,norms and sanctions,nuclear nonproliferation,financial regulation
Therapeutic immunotherapy targeting NG2 and CD22 antigens for MLL-rearranged and MLL-germline B-cell Acute Lymphoblastic Leukemia (IT4B-ALL)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Spain
Call: ERC Proof of Concept Grant (ERC-2018-PoC, 2018)
Start date: 2019-01-01
End date: 2020-06-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

B-ALL is the commonest cancer of childhood. There remain childhood B-ALL subgroups with dismal prognosis such as infant B-ALL and B-ALL carrying MLL rearrangements (MLLr). In addition, the prognosis of adult B-ALL is worse, and refractory/relapse (R/R) B-ALL remains dismal. CD19-targeted immunotherapies have emerged as promising therapeutic approaches for R/R B-ALL. CD19 CAR T-cells have shown impressive efficacy in R/R B-ALL. However, relatively rapid relapses are frequently observed, a proportion of them losing CD19 expression upon CAR19 T-cell therapy due to massive antigen pressure over CD19, resulting in a myeloid lineage switch in MLLr B-ALL, or the selection of CD19-/CD34+ preleukemic progenitors. Further CD19-targeted therapy is thus ineffectual for CD19neg R/R B-ALL. Our overarching goal is to provide novel therapeutic options for (R/R) B-ALL.Targeting surface antigens whose expression, opposite to CD19, are commonly retained at relapse is a valid strategy to circumvent the loss of CD19 found in (R/R) B-ALL after CD19-targeted therapies. Recent work funded by my ERC-2014-CoG has identified NG2 and CD22 as key antigens to be targeted in (R/R) B-ALL. First, both antigens are retained in CD19neg R/R B-ALL. Second, NG2 is solely expressed in MLLr B-ALL, and is associated with CNS infiltration, aggressiveness and glucocorticoid resistance. Third, CD22 is a pan-B marker expressed developmentally earlier than CD19, and CD34+CD22+CD19- cells may represent pre-malignant progenitors escaping the CD19-targeted pressure. These results have just been protected by a European Patent (EPI173825514), and are the proof-of-principle demonstration of NG2 & CD22 representing promising immunotherapeutic targets, when combined with CD19 for both MLLr & MLL-germline B-ALL, respectively. Here we propose to consolidate preclinical work and GMP production of anti-NG2 monoclonal antibody and NG2/CD19 and CD22/CD19 CAR T-cells to launch a PhaseI academic clinical trial for R/R B-ALL

Keywords: b cell acute lymphoblastic leukemia,relapse b all,car t cells,ng2 antigen,cd22,tandem cars,mll rearrangement,clinical development,phase i clinical trial